Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Marta Herreros‐Villanueva

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6905-0693; OpenAlex author ID A5016221172. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 18

  1. Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome. Last author DOI 10.1016/j.dld.2025.09.025↗
  2. Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. Co-author DOI 10.3390/cancers16223779↗
  3. Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing. Co-author DOI 10.1016/j.gastrohep.2021.12.011↗
  4. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Co-author DOI 10.1007/s11033-020-05245-5↗
  5. Dealing with pancreatic cancer in two different ways. Co-author DOI 10.1016/j.cca.2017.05.025↗
  6. Pancreatic Cancer in Lynch Syndrome Patients. First author DOI 10.7150/jca.20750↗
  7. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Co-author DOI 10.21037/atm.2016.03.44↗
  8. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. Co-author DOI 10.3978/j.issn.2305-5839.2015.10.39↗
  9. Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000000373↗
  10. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. First author DOI 10.1038/cddis.2014.102↗
  11. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells First author DOI 10.1038/cddis.2014.341↗
  12. Embryonic stem cell factors and pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i9.2247↗
  13. Molecular markers in pancreatic cancer diagnosis. Co-author DOI 10.1016/j.cca.2012.12.025↗
  14. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Co-author DOI 10.1038/oncsis.2013.23↗
  15. Mouse models of pancreatic cancer. Co-author DOI 10.3748/wjg.v18.i12.1286↗
  16. Adjuvant and neoadjuvant treatment in pancreatic cancer. Co-author DOI 10.3748/wjg.v18.i14.1565↗
  17. Spontaneous regression of pancreatic cancer: real or a misdiagnosis? Co-author DOI 10.3748/wjg.v18.i23.2902↗
  18. c-Met in pancreatic cancer stem cells: therapeutic implications. Co-author DOI 10.3748/wjg.v18.i38.5321↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luís Bujanda · 12 shared papers, 2013–2025 · strength 1.29
  2. Leticia Moreira · 2 shared papers, 2024–2025 · strength 0.38
  3. María Consuelo Artigas · 1 shared paper, 2022 · strength 0.17
  4. Joan Llach · 1 shared paper, 2024 · strength 0.16
  5. Fabio Ausania · 1 shared paper, 2024 · strength 0.16
  6. Julie Earl · 1 shared paper, 2024 · strength 0.16
  7. Alexander Otto König · 3 shared papers, 2013–2014 · strength 0.11
  8. Daniel D. Billadeau · 3 shared papers, 2013–2014 · strength 0.11
  9. Enrique de‐Madaria · 1 shared paper, 2020 · strength 0.09
  10. Volker Ellenrieder · 2 shared papers, 2014 · strength 0.08
  11. Zhang Js · 2 shared papers, 2013–2014 · strength 0.07
  12. Meritxell Gironella · 1 shared paper, 2013 · strength 0.05
  13. J-S Zhang · 1 shared paper, 2014 · strength 0.04
  14. Zhi-Hui Deng · 1 shared paper, 2014 · strength 0.04
  15. Thomas C. Smyrk · 1 shared paper, 2013 · strength 0.03
  16. Diane M. Simeone · 1 shared paper, 2013 · strength 0.03
  17. Ethan V. Abel · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.